Drug Discovery World
JULY 11, 2022
Biotechnology company Awakn Life Sciences has received funding from Innovate UK to help it advance its ketamine-assisted therapy programme to market in the UK and US. . Awakn Life Sciences has developed a ketamine-assisted therapy programme for treating alcohol use disorder (AUD). The company plans to work with clinical research organisation (CRO) Veristat to deliver its programmes. .
Antidote
JULY 13, 2022
Before a potential new therapy can be administered to patients, it must go through several clinical trial phases designed to test the drug or device for safety and effectiveness. For many new treatments, it will take approximately ten years for the therapy to progress from initial discovery to being approved. Clinical trials alone take six to seven years on average to complete.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JULY 15, 2022
Today’s guest post comes from Carolyn Zele, Senior Manager of Solution Enablement at MMIT. Carolyn explains the advantages of alternative payment models (APM) for measuring and rewarding value and outcomes in our healthcare system. For more on how APMs measure value, click here to learn about MMIT’s Pulse Analytics Solution. Read on for Carolyn’s insights.
Olympian Clinical Research
JULY 12, 2022
Depression is an illness that affects nearly 280 million people worldwide. There are several types of depression, each with its own set of symptoms and recommended treatment methods. Therefore, overcoming depression requires understanding the type of depression you may be facing and getting the proper help. 1. Major Depressive Disorder. Major depressive disorder ( MDD ), also known as clinical depression, is characterized by a persistent feeling of sadness or emptiness lasting for at least two w
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Discovery World
JULY 15, 2022
Single cell and spatial tools from 10x Genomics are designed to deliver powerful, multiomic insights from complex disease samples that enable you to confidently fuel your target identification pipeline with the most promising candidates. Resolving complex biology with single cell and spatial multiomics will be presented by Stephen Hague, Managing Lead Science & Technology Advisor EMEA, 10x Genomics.
Drug Patent Watch
JULY 15, 2022
Annual Drug Patent Expirations for FOLOTYN Folotyn is a drug marketed by Acrotech and is included in one NDA. It is available from one supplier. There are three patents protecting…. The post New patent expiration for Acrotech drug FOLOTYN appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Translation
JULY 13, 2022
Valent U.S.A. and Valent Biosciences are subsidiaries of Japan’s $30 billion Sumitomo Chemical Company. Last year, the companies partnered with Halo to seek solutions in carbon sequestration , plant growth regulators , and mycorrhizal fungi colonization. Among proposals from nearly 100 universities, Valent U.S.A. and Valent Biosciences selected four researchers (including one research team) for fully-funded one year projects, with the opportunity for extension based on year-end results. “T
Drug Discovery World
JULY 15, 2022
News round-up by DDW’s Reece Armstrong for 11 – 15 July. Urgency a must for global fight against AMR, report says. Urgent access to vaccines that can fight and prevent infections, and curb the risk of antimicrobial resistance (AMR) is needed to save lives, according to a report by the World Health Organisation (WHO). Could this drug help repair nerve damage?
Drug Patent Watch
JULY 15, 2022
Annual Drug Patent Expirations for GALAFOLD Galafold is a drug marketed by Amicus Therap Us and is included in one NDA. There are thirty-five patents protecting this drug. This drug…. The post New patent for Amicus Therap drug GALAFOLD appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
JULY 11, 2022
Informa Connect's Hub and Specialty Pharmacy Models West. Delivered as a Hybrid Event. September 14-15, 2022 Sheraton San Diego Hotel & Marina | San Diego, CA www.informaconnect.com/hub-specialty-pharmacy-west. Drug Channels readers will save 10% off the current registration rate when they use code 22DC10 *. This important event convenes key stakeholders including manufacturers, specialty pharmacies, hub providers and more for unrivaled collaboration to leverage innovation and optimize acces
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Nvidia Developer: Drug Discovery
JULY 14, 2022
Drug discovery startup Insilico Medicine—alongside researchers from Harvard Medical School, Johns Hopkins School of Medicine, the Mayo Clinic, and. Drug discovery startup Insilico Medicine—alongside researchers from Harvard Medical School, Johns Hopkins School of Medicine, the Mayo Clinic, and others—used AI to identify more than two dozen gene targets related to amyotrophic lateral sclerosis (ALS).
Drug Discovery World
JULY 15, 2022
Pharmaceutical company Transpire Bio will work alongside drug delivery provider Recipharm to develop two inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).? . Transpire Bio announced a definitive agreement with Recipharm to develop its TRB-1 and TRB-2 inhaled medicines. These are the first products developed by Transpire Bio and will be indicated for the treatment of asthma and COPD, intended for advanced markets. .
Drug Patent Watch
JULY 15, 2022
Annual Drug Patent Expirations for VOSEVI Vosevi is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are eighteen…. The post New patent for Gilead Sciences drug VOSEVI appeared first on DrugPatentWatch - Make Better Decisions.
Tecan
JULY 11, 2022
By Dajana Domik Neopterin is a valuable diagnostic biomarker which can be applied in research and in clinical settings. As an inflammation marker, it is a global “catch all” biomarker that serves as an early warning system for many different diseases without the need to perform a battery of tests. But how do you decide which neopterin test is right for your lab?
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
PerkinElmer
JULY 12, 2022
Earlier this year, the World Health Organization (WHO) announced that over one million African children had received one or more doses of the world’s first malaria vaccine, RTS,S/AS01 (RTS,S). 1 If widely deployed, the WHO estimates that the vaccine, which is the result of 30 years of research, could save the lives of an additional 40,000 to 80,000 African children each year.
Drug Discovery World
JULY 14, 2022
Life sciences organisation Cytiva has acquired a new facility in Michigan US to help it expand its resins manufacturing operations outside of Sweden. . The company’s new chromatography resins manufacturing site will be based in Muskegon, Michigan and forms part of Cytiva and Pall Corporation’s $1.5 billion capacity expansion investment. . Cytiva plans to transform the site into a 168,000 square-foot biomanufacturing centre.
Drug Patent Watch
JULY 14, 2022
Annual Drug Patent Expirations for EPIDIOLEX Epidiolex is a drug marketed by Gw Res Ltd and is included in one NDA. It is available from one supplier. There are twenty-two…. The post New patent for Gw Res drug EPIDIOLEX appeared first on DrugPatentWatch - Make Better Decisions.
Antidote
JULY 11, 2022
It’s common for people to have trouble seeing things close up as they age — this condition is called presbyopia, and it affects millions of people in the United States. Whether it’s reading a menu with ease or not having to strain to look at a phone screen, treatments for this condition can greatly improve the quality of life for those impacted.
Crown Bioscience
JULY 10, 2022
Precision medicine and immunotherapy continue to top the list as two of the hottest areas in cancer research. In this blog post we explore how immuno-oncology can draw from precision medicine to create more personalized cancer therapies to enhance their safety and efficacy. Read on to review how ICIs, neoantigen vaccines and adoptive cell therapies, including CAR-T, CAR-NK, CAR-M, TCR-T and TIL therapies, are advancing this remarkable field of science and medicine.
Drug Discovery World
JULY 14, 2022
Pharmaceutical company SIGA Technologies has announced that its oral therapy tecovirimat has been approved in the UK for the treatment of smallpox, monkeypox, cowpox. . The therapy has also been approved for the treatment of complications following vaccination against smallpox in adults and children with a body weight of at least 13kg. . Tecovirimat works by interfering with the VP37 protein which is found on the surface of orthopoxviruses such as smallpox and monkeypox.
Drug Patent Watch
JULY 14, 2022
Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Atomwise Blog
JULY 11, 2022
Our scientists developed AtomNet® PoseRanker to improve our technology’s ability to rank poses for protein-ligand interactions with potential drug compounds Identifying the highest-quality protein-ligand poses generated from structure-based virtual high-throughput screening (vHTS) approaches is a major challenge for drug discovery. These methods typically use a physics-based scoring function to generate ranked lists of plausible poses, which are models of physical interactions between small mole
Drug & Device Law
JULY 12, 2022
While two-fer Tuesday has that nice alliterative ring to it – three-fer Tuesday gives you more bang for your buck. Pleadings, preemption, and personal jurisdiction. Maybe trifecta-Tuesday? Plaintiff in Froman v. Coopersurgical, Inc. , 2022 US Dist LEXIS 120725, *2-3 (N.D.AL Jul. 8, 2022) filed her complaint alleging that she suffered an injury when a device implanted during her tubal ligation surgery migrated requiring explantation seven years later.
Drug Discovery World
JULY 14, 2022
Biotech company Actigen has moved closer to clinical trials for rare disease treatment for Hunter syndrome, following a pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA). ? . The Cambridge-based biotech filed for a pre-IND advice meeting with the FDA to discuss the scientific, regulatory and safety issues related to developing GNR-055 – the company’s new rare disease treatment for mucopolysaccharidosis II, otherwise known as MPS II or Hunter syndrome. .
Drug Patent Watch
JULY 14, 2022
Annual Drug Patent Expirations for ARMONAIR+DIGIHALER Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are twenty…. The post New patent for Teva Pharm drug ARMONAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery World
JULY 13, 2022
Novo Nordisk has announced positive interim results for its Mim8 antibody which is being as a treatment for haemophilia A. . Novo Nordisk presented interim results from the Phase I & II FRONTIER1 dose-escalation study at International Society of Thrombosis and Haemostasis Annual Congress (ISTH 2022) in London, UK.?? . The study is assessing the safety and clinical use of Mim8 in patients with haemophilia A.
Drug Discovery World
JULY 13, 2022
The first new treatment in 20 years that prevents a common, painful side-effect in patients with sickle cell disorder (SCD) has been issued interim acceptance by the Scottish Medicines Consortium (SMC). . The SMC issued interim acceptance for Novartis UK’s Adakveo for use in NHS Scotland as a treatment option for the prevention of recurrent vaso-occlusive crises (VOC) in SCD patients.
Drug Discovery World
JULY 12, 2022
Research from the University of Birmingham in the UK has indicated that a cancer therapy could help damaged nerves repair themselves following spinal injury. . The research shows that AstraZeneca’s candidate drug AZD1390 can block the response to DNA damage in nerve cells and promote regeneration of damaged nerves, restoring sensory and motor function after spinal injury.?
Drug Discovery World
JULY 12, 2022
Urgent access to vaccines that can fight and prevent infections, and curb the risk of antimicrobial resistance (AMR) is needed to save lives, according to a report by the World Health Organisation (WHO). . WHO has released the first-ever report 1 looking at the pipeline of vaccines currently in development to fight infections caused by (AMR) . It outlines that whilst there are 61 vaccine candidates in clinical development targeting diseases listed on WHO’s bacterial priority pathogen list 2 ,
Drug Discovery World
JULY 12, 2022
Automation has long been a buzzword associated with cutting-edge science, yet even in the most advanced labs it is usually only applied to specific assays and methods. However, by building automation across your full laboratory workflows and integrating it into existing protocols, Biotech R&D can be transformed. In this FREE TO REGISTER webinar, Russ Green, Product Lead at Automata Technologies, discusses the key pillars of automation across laboratory environments to increase throughput, en
Drug Discovery World
JULY 12, 2022
Automation has long been a buzzword associated with cutting-edge science, yet even in the most advanced labs it is usually only applied to specific assays and methods. However, by building automation across your full laboratory workflows and integrating it into existing protocols, Biotech R&D can be transformed. In this FREE TO REGISTER webinar, Russ Green, Product Lead at Automata Technologies, discusses the key pillars of automation across laboratory environments to increase throughput, en
Drug Discovery World
JULY 12, 2022
Origin Therapeutics, an investment company focused on psychedelic therapies, has added Canadian biotech Clairvoyant to its portfolio. . Clairvoyant is developing psychedelic drug therapy focused on addiction and is targeting the clinical validation of psilocybin in the EU, the UK, and Canada. The company is currently proceeding with a Phase II clinical trial in Canada for the clinical validation of psilocybin for the treatment of alcohol use disorder (AUD).
Drug Discovery World
JULY 12, 2022
Biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation to help the company advance its lead compound for cystic fibrosis patients who have been infected with methicillin-resistant? Staphylococcus aureus ?(MRSA). . Destiny Pharma will establish a research project with the Cystic Fibrosis Foundation where it will establish the potential of its XF-73 drug as a treatment for MRSA infected cystic fibrosis patients. .
Drug Discovery World
JULY 11, 2022
Pharmaceutical company Novo Nordisk has announced positive results for its prophylactic treatment targeting people living with haemophilia A or B with inhibitors. . The company’s concizumab treatment is an anti-tissue factor pathway inhibitor (TFPI)? antibody in development to prevent prolonged and spontaneous bleeding in all types of haemophilia. .
Expert insights. Personalized for you.
246 
Let's personalize your content